Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | GLA | P06280 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 8/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 4/20 | 0.54 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2056354 | 0.86 | LMNA (0.59) | KDM4EGLAGAAALDH1A1HPGD | |
| SCHEMBL13245001 | 0.83 | ALDH1A1 (0.54) | KDM4EGLAGAAALDH1A1HPGD | |
| SCHEMBL18021723 | 0.80 | AR (0.63) | KIF11 | |
| SCHEMBL31369133 | 0.79 | KIF11 (0.65) | KDM4EGLAGAAALDH1A1HPGD | |
| SCHEMBL31369143 | 0.79 | KIF11 (0.65) | KDM4EGLAGAAALDH1A1HPGD | |
| SCHEMBL2606005 | 0.78 | KIF11 (0.81) | ALDH1A1HPGDKIF11MAPTHSD17B10 | |
| SCHEMBL29539315 | 0.78 | KIF11 (0.81) | ALDH1A1HPGDKIF11MAPTHSD17B10 | |
| SCHEMBL2795205 | 0.77 | KDM4E (0.67) | KDM4EGLAGAAALDH1A1HPGD | |
| Bromide SCHEMBL30567841 | 0.77 | KIF11 (0.78) | ALDH1A1HPGDKIF11MAPTHSD17B10 | |
| SCHEMBL13244957 | 0.75 | KIF11 (0.54) | KDM4EALDH1A1HPGDSMN1; SMN2TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10241116-B2 | Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170016907-A1 | DUAL-SENSITIZER-CONTAINING LUMINESCENT COMPOUNDS, CONJUGATES, AND USES THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170016907-A1 | DUAL-SENSITIZER-CONTAINING LUMINESCENT COMPOUNDS, CONJUGATES, AND USES THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-01-19 | — | — | US | disclosed |
| US-9415111-B2 | Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170016907-A1 | DUAL-SENSITIZER-CONTAINING LUMINESCENT COMPOUNDS, CONJUGATES, AND USES THEREOF | DYRK4, DYRK2, DYRK3 | KDM4E 2347/4885GLA 1328/4885GAA 473/4885 |
| US-10241116-B2 | Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof | DYRK4, DYRK2, DYRK3 | KDM4E 2347/4885GLA 1328/4885GAA 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.